HOUSTON, Sept. 1, 2026 /PRNewswire/ — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,716,055, titled “Treatment of Disc Degenerative Disease and Stimulation of Proteoglycan Synthesis by Fibroblast Conditioned Media and Formulations Thereof.”

The patent covers methods of promoting disc regeneration by administering fibroblast cells that have been cultured with one or more opioid receptor antagonists and toll-like receptor (TLR) agonists. These compounds, including opioid receptor antagonists such as naltrexone, stimulate fibroblasts to increase the production of regenerative growth factors, including epidermal growth factor (EGF). Conditioned media and other components derived from these stimulated fibroblasts may then be delivered to a patient, either directly into the disc or systemically, to promote disc regeneration and stimulate proteoglycan synthesis.